Johnson & Johnson (NYSE:JNJ) Shares Sold by Builder Investment Group Inc. ADV

Builder Investment Group Inc. ADV cut its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,962 shares of the company’s stock after selling 100 shares during the period. Johnson & Johnson makes up 1.2% of Builder Investment Group Inc. ADV’s holdings, making the stock its 23rd biggest holding. Builder Investment Group Inc. ADV’s holdings in Johnson & Johnson were worth $4,333,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of JNJ. Flywheel Private Wealth LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at $514,000. Winch Advisory Services LLC boosted its stake in Johnson & Johnson by 13.9% during the fourth quarter. Winch Advisory Services LLC now owns 3,316 shares of the company’s stock worth $479,000 after buying an additional 404 shares during the period. Smith Thornton Advisors LLC increased its position in shares of Johnson & Johnson by 2.5% during the fourth quarter. Smith Thornton Advisors LLC now owns 3,909 shares of the company’s stock valued at $565,000 after acquiring an additional 96 shares during the last quarter. Outlook Wealth Advisors LLC raised its stake in shares of Johnson & Johnson by 19.4% in the 4th quarter. Outlook Wealth Advisors LLC now owns 13,266 shares of the company’s stock valued at $1,919,000 after acquiring an additional 2,159 shares during the period. Finally, Stolper Co boosted its position in shares of Johnson & Johnson by 1.5% during the 4th quarter. Stolper Co now owns 34,295 shares of the company’s stock worth $4,960,000 after purchasing an additional 496 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have issued reports on JNJ shares. Bank of America cut their target price on Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a research report on Friday. Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $174.29.

Johnson & Johnson Trading Down 0.5 %

Shares of NYSE:JNJ opened at $147.03 on Friday. The company has a market cap of $353.99 billion, a PE ratio of 21.28, a P/E/G ratio of 2.30 and a beta of 0.51. The company’s 50 day moving average is $148.68 and its two-hundred day moving average is $155.96. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the firm earned $2.66 earnings per share. Equities analysts predict that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.